Fig. 5From: Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practiceProgression free survival (a) and overall survival (b) in patients with or without extramedullary plasmocytoma (EMD) treated by IRD or RD regimenBack to article page